StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen's (AMGN) NDA for Etelcalcetide Accepted by FDA
November 6, 2015 4:02 PM
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's New Drug ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22
November 9, 2015 7:32 AM
FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide
November 6, 2015 4:01 PM